Your browser doesn't support javascript.
loading
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
Sorce, Gabriele; Hoeh, Benedikt; Flammia, Rocco S; Chierigo, Francesco; Hohenhorst, Lukas; Panunzio, Andrea; Nimer, Nancy; Tian, Zhe; Gandaglia, Giorgio; Tilki, Derya; Terrone, Carlo; Gallucci, Michele; Chun, Felix K H; Antonelli, Alessandro; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.
Afiliação
  • Sorce G; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Hoeh B; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Flammia RS; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Chierigo F; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
  • Hohenhorst L; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Panunzio A; Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University Rome, Rome, Italy.
  • Nimer N; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tian Z; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
  • Gandaglia G; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Terrone C; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Gallucci M; Department of Urology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy.
  • Chun FKH; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Antonelli A; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Saad F; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Shariat SF; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Montorsi F; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Briganti A; Department of Urology, Koc University Hospital, Istanbul, Turkey.
  • Karakiewicz PI; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Prostate ; 82(12): 1210-1218, 2022 09.
Article em En | MEDLINE | ID: mdl-35652586
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Prostate Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Idioma: En Revista: Prostate Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália